1. Home
  2. STXS vs ENTA Comparison

STXS vs ENTA Comparison

Compare STXS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STXS
  • ENTA
  • Stock Information
  • Founded
  • STXS 1990
  • ENTA 1995
  • Country
  • STXS United States
  • ENTA United States
  • Employees
  • STXS N/A
  • ENTA N/A
  • Industry
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ENTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • STXS Health Care
  • ENTA Health Care
  • Exchange
  • STXS Nasdaq
  • ENTA Nasdaq
  • Market Cap
  • STXS 151.3M
  • ENTA 160.3M
  • IPO Year
  • STXS 2004
  • ENTA 2013
  • Fundamental
  • Price
  • STXS $2.13
  • ENTA $7.28
  • Analyst Decision
  • STXS
  • ENTA Buy
  • Analyst Count
  • STXS 0
  • ENTA 4
  • Target Price
  • STXS N/A
  • ENTA $18.00
  • AVG Volume (30 Days)
  • STXS 207.9K
  • ENTA 168.6K
  • Earning Date
  • STXS 08-11-2025
  • ENTA 08-04-2025
  • Dividend Yield
  • STXS N/A
  • ENTA N/A
  • EPS Growth
  • STXS N/A
  • ENTA N/A
  • EPS
  • STXS N/A
  • ENTA N/A
  • Revenue
  • STXS $27,510,000.00
  • ENTA $64,462,999.00
  • Revenue This Year
  • STXS $25.90
  • ENTA N/A
  • Revenue Next Year
  • STXS $60.57
  • ENTA $0.48
  • P/E Ratio
  • STXS N/A
  • ENTA N/A
  • Revenue Growth
  • STXS 1.50
  • ENTA N/A
  • 52 Week Low
  • STXS $1.54
  • ENTA $4.09
  • 52 Week High
  • STXS $2.72
  • ENTA $17.24
  • Technical
  • Relative Strength Index (RSI)
  • STXS 47.58
  • ENTA 60.14
  • Support Level
  • STXS $2.06
  • ENTA $6.87
  • Resistance Level
  • STXS $2.36
  • ENTA $8.47
  • Average True Range (ATR)
  • STXS 0.11
  • ENTA 0.50
  • MACD
  • STXS -0.01
  • ENTA -0.03
  • Stochastic Oscillator
  • STXS 19.70
  • ENTA 54.44

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Share on Social Networks: